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Introduction: Although aberrant tyrosine kinase signalling characterises particular breast cancer subtypes, a global
analysis of tyrosine phosphorylation in mouse models of breast cancer has not been undertaken to date. This may
identify conserved oncogenic pathways and potential therapeutic targets.
Methods: We applied an immunoaffinity/mass spectrometry workflow to three mouse models: murine stem cell
virus-Neu, expressing truncated Neu, the rat orthologue of human epidermal growth factor receptor 2, Her2
(HER2); mouse mammary tumour virus-polyoma virus middle T antigen (PyMT); and the p53−/− transplant model
(p53). Pathways and protein–protein interaction networks were identified by bioinformatics analysis. Molecular
mechanisms underpinning differences in tyrosine phosphorylation were characterised by Western blot analysis and
array comparative genomic hybridisation. The functional role of mesenchymal–epithelial transition factor (Met) in a
subset of p53-null tumours was interrogated using a selective tyrosine kinase inhibitor (TKI), small interfering
RNA (siRNA)–mediated knockdown and cell proliferation assays.
Results: The three models could be distinguished on the basis of tyrosine phosphorylation signatures and
signalling networks. HER2 tumours exhibited a protein–protein interaction network centred on avian erythroblastic
leukaemia viral oncogene homologue 2 (Erbb2), epidermal growth factor receptor and platelet-derived growth
factor receptor α, and they displayed enhanced tyrosine phosphorylation of ERBB receptor feedback inhibitor 1. In
contrast, the PyMT network displayed significant enrichment for components of the phosphatidylinositol 3-kinase
signalling pathway, whereas p53 tumours exhibited increased tyrosine phosphorylation of Met and components
or regulators of the cytoskeleton and shared signalling network characteristics with basal and claudin-low breast
cancer cells. A subset of p53 tumours displayed markedly elevated cellular tyrosine phosphorylation and Met
expression, as well as Met gene amplification. Treatment of cultured p53-null cells exhibiting Met amplification
with a selective Met TKI abrogated aberrant tyrosine phosphorylation and blocked cell proliferation. The effects on
proliferation were recapitulated when Met was knocked down using siRNA. Additional subtypes of p53 tumours
exhibited increased tyrosine phosphorylation of other oncogenes, including Peak1/SgK269 and Prex2.
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Conclusion: This study provides network-level insights into signalling in the breast cancer models utilised
and demonstrates that comparative phosphoproteomics can identify conserved oncogenic signalling
pathways. The Met-amplified, p53-null tumours provide a new preclinical model for a subset of triple-negative
breast cancers.Introduction
It is well established that tyrosine kinase signalling path-
ways play major roles in breast cancer development and
progression. Evidence for this includes (1) the amplifica-
tion of the receptor tyrosine kinase (RTK) human epider-
mal growth factor receptor 2 (HER2)/avian erythroblastic
leukaemia viral oncogene homologue 2 (erbB2) in appro-
ximately 25% of breast cancers [1]; (2) the presence of
activating mutations in PIK3CA, encoding the p110α
catalytic subunit of phosphatidylinositol 3-kinase (PI3K),
in approximately 30% of cases [2]; and dysregulation of
other signalling intermediates such as the non-RTK Src
[3], the docking protein Gab2 [4] and the serine/threonine
kinase Akt3 [5]. In addition, an array of data from cell line
and mouse models of breast cancer confirm the oncogenic
or tumour suppressor roles of particular tyrosine-phos-
phorylated signalling proteins [6-9]. These findings have
led to the development of small-molecule– and antibody-
based targeted therapies that have either entered the clinic
or are currently undergoing clinical trials, including the use
of trastuzumab to treat HER2-positive breast cancer [10].
Gene expression profiling has revealed that breast can-
cer can be subclassified into luminal A, luminal B,
HER2, basal and claudin-low subtypes, which differ in
terms of patient prognosis and response to therapy [11].
Basal and claudin-low breast cancers present a major
clinical challenge, as their frequent triple-negative pheno-
type (lacking HER2, oestrogen and progesterone recep-
tors) confers intrinsic resistance to HER2-targeted and
endocrine therapy [12]. The HER2 subtype is charac-
terised by amplification of the corresponding gene, and
other breast cancer subtypes also exhibit characteristic
perturbations in tyrosine kinase signalling. For example,
increased expression of the RTKs Met and epidermal
growth factor receptor (Egfr) are associated with basal and
triple-negative breast cancers [13-15], and, at least in cell
line models, the basal and claudin-low subtypes are char-
acterised by a prominent Src family kinase (SFK)–gov-
erned network [16,17]. Further characterisation of the
signalling networks associated with different breast cancer
subtypes may identify novel therapeutic targets and new
applications for existing therapies, as well as biomarkers
that aid patient stratification for therapy.
Genetically engineered mouse (GEM) models have
greatly contributed to our understanding of the mecha-
nisms and functions of particular oncogenes and tumoursuppressors implicated in breast cancer, as well as
biological processes involved in tumour progression
[18]. These include GEM models in which normal or
activated forms of neu (the rat homologue of HER2/
erbB2) are expressed in the mammary gland [8], as
well as the polyoma virus middle T antigen (PyMT) model
[19]. PyMT mimics an activated RTK, localising to the
plasma membrane, as well as in intracellular membranes,
where it is phosphorylated on specific tyrosine residues by
particular SFKs. Phosphorylation of PyMT creates binding
sites for Shc (at Y250), the p85 subunit of PI3K (at Y315)
and phospholipase Cγ1 (PLCγ1, at Y322), and key roles
for the Y250 and Y315/Y322 sites in mammary tumouri-
genesis have been demonstrated [20]. Interestingly, tran-
script profiling has demonstrated that mouse mammary
tumour virus (MMTV)-Neu and MMTV-PyMT model
tumours are relatively homogeneous and exhibit gene
expression similarities to human luminal-type cancers [21].
In contrast, the p53-null transplant model of mammary
tumourigenesis is characterised by tumours exhibiting his-
tological and molecular heterogeneity, as well as genetic
instability [22,23]. Indeed, transcript profiling has demon-
strated that p53-null tumours can be classified into basal-
like, luminal and claudin-low subtypes characterised by
distinct genomic copy number changes [22].
An important concept emanating from research using
GEM models is that comparative genomic and transcrip-
tomic strategies, wherein particular mouse tumours are
compared to human breast cancer subtypes, can be uti-
lised identify conserved mechanisms essential for disease
development and progression [21,22,24,25]. In this study,
we undertook global tyrosine phosphorylation profiling of
three GEM models of breast cancer: a HER2 model featur-
ing expression of an activated form of the receptor lacking
the extracellular domain [26], as well as the MMTV-PyMT
and p53-null transplant models. This enabled characte-
risation of the tyrosine phosphorylation-based signalling
networks characteristic of each tumour type, revealed simi-
larities and differences between these tumour models, and
identified oncogenic pathways conserved in the human
disease.
Methods
Plasmids
Neu-pMIL was used to generate the HER2 breast
cancer model. This expresses a truncated form of Neu
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thologue of Her2) with elevated activity due to truncation
of the extracellular domain [27]. Truncated Neu was sub-
cloned from Neu-pLJ by digestion using Sal1 followed by
subcloning into pENTR2B (Invitrogen, Mulgrave, Victoria,
Australia). The gene was subsequently cloned into pMIL,
a derivative of pMig [28] that expresses a luciferase marker,
to generate Neu-pMIL, in which expression of Neu is
driven by the murine stem cell virus (MSCV) promoter.
The Gateway LR recombination reaction was used as per
the manufacturer’s instructions (Invitrogen).
Generation of tumours
MSCV-Neu (HER2) tumours
Primary mammary epithelial cells from FVB/N mice
were cultured and retrovirally transduced with trun-
cated Neu encoded by Neu-pMIL as described previously
[26,29,30]. Cells were transplanted into the cleared mam-
mary fat pad of naïve FVB/N recipients within 2 days of
retroviral transduction.
Tp53-null tumours
Tp53-null (p53) mice from The Jackson Laboratory
(stock no. 002899; Bar Harbor, ME, USA) were on an
FVB/N background. Mammary epithelium from 8-week-
old mice was transplanted to the cleared mammary fat
pad of naïve BL/6 (clone 5101) or FVB/N (all other clones)
recipients as described previously [16,31].
Mice were aged for up to 12 months to permit spontan-
eous tumour formation [26]. Tumour fragments were pas-
saged into the cleared mammary fat pad of naïve mice as
previously described [26] (Additional file 1: Figure S1).
PyMT-transformed tumours
PyMT tumours were derived from MMTV-PyMT-trans-
genic mice on an FVB/N background as previously de-
scribed [32]. All animal work was approved by the animal
ethics committee of Garvan Institute of Medical Research,
St Vincent’s Hospital.
Phosphotyrosine peptide enrichment
Resected mouse mammary tumours were lysed in 8 M
urea, 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-
sulfonic acid (HEPES), 2.5 mM sodium pyrophosphate,
1 mM β-glycerol phosphate, 1 mM sodium orthova-
nadate, 1 mM ethylenediaminetetraacetic acid and 1 mM
Tris(2-carboxyethyl)phosphine, pH 8.0. Lysates were cleared
by sonication and centrifugation prior to protease diges-
tion, phosphotyrosine (pY) immunoprecipitation (IP) and
nano-liquid chromatography tandem mass spectrometry
(nano-LC-MS/MS). Lysates were quantitated, and 20 mg
of each sample were diluted to a final concentration of
1 M urea with 20 mM HEPES and digested overnight with
trypsin at room temperature. Heavy proline (+6 Da)– andalanine (+4 Da)–labelled synthetic standard pY peptides
of MK14, elongation factor Tu and EGFR were spiked into
each sample at 5 pmol, 500 fmol and 10 pmol, respect-
ively, to enable normalisation of label-free quantitative
values. Peptides were then desalted and concentrated
using C18 Sep-Pak columns (Waters, Milford, MA, USA),
and lyophilised. pY peptides were subject to IP using
the PhosphoScan procedure (Cell Signaling Technology,
Beverly, MA, USA) with pY100 antibodies as previously
described [16]. pY-enriched peptides were dried using
a vacuum centrifuge and stored at −80°C prior to nano-
LC-MS/MS analysis. All samples were analysed by nano-
LC-MS/MS using two technical replicates.
Nano–liquid chromatography tandem mass spectrometry
pY peptides were resuspended in 15 μl of MS buffer
containing 1% formic acid, 2% acetonitrile (ACN) and
0.05% heptafluorobutyric acid and subjected to nano-
LC-MS/MS. Peptides were separated by nano-LC using
an UltiMate 3000 high-performance liquid chromatography
and autosampler system (Dionex, Sunnyvale, CA, USA).
Samples were concentrated and desalted onto a C18 micro-
precolumn (500 μm× 2 mm; Michrom Bioresources,
Auburn, CA, USA) with H2O:ACN (98:2, 0.05% trifluoroa-
cetic acid) at 15 μl/min for 4 minutes. The micro-precol-
umn was then switched online with a nano-C18 column
(75 μm× about 10 cm, 5 μm, 200 Å Magic; Michrom) and
the reverse phase nano-eluent was subjected to positive
nanoflow electrospray analysis in information-dependent
acquisition (IDA) mode (250 nl/min for 30 minutes).
Mass spectra were acquired on an Orbitrap Velos mass
spectrometer (Thermo Electron, Waltham, MA, USA).
In IDA mode, survey scans in the mass-to-charge ratio
(m/z) range 350 to 1,750 were acquired with lock mass
enabled. Up to the 15 most abundant ions (>5,000 counts)
with charge states greater than +2 were sequentially
isolated and further subjected to MS/MS fragmentation
within the linear ion trap using collisionally induced
dissociation. MS/MS spectra were accumulated with an
activation time of 30 milliseconds at a target value of
30,000 ions and a resolution of 60,000. m/z ratios
selected for MS/MS were dynamically excluded for
30 seconds.
Protein identification
The nano-LC-MS/MS .raw files were processed with
MaxQuant software (version 1.1.1.25), which uses the
Andromeda algorithm for data processing, database search-
ing and protein identification [33]. Extracted peak lists were
searched against the UniProtKB/Swiss-Prot Mus musculus
database (Version 2010_10) containing 35,052 entries
(including common contaminants) and a proportionally
sized decoy database for false discovery rate (FDR) gener-
ation. The following search parameters were selected:
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able methionine oxidation modification, variable protein
N-acetylation, and variable phosphorylation of serine,
threonine and tyrosine. A minimum peptide length of six
amino acids and up to two missed cleavages were allowed.
The initial first search mass tolerance was 20 ppm for
precursor ions and 0.5 Da for fragment ions. Matches
between runs were enabled with default settings and
label-free quantitation enabled. The FDR was limited
to 1% for both protein and peptide identification. For
identification of the standard peptides, additional variable
modifications of heavy proline (+6 Da) and alanine (+4 Da)
were enabled.
Phosphotyrosine peptide quantitation
Raw pY peptide spectral intensities were extracted from
the ‘Evidence’ output files generated in MaxQuant. These
intensities were then normalised against pY peptide inten-
sities for the heavy-labelled spiked-in peptide standards.
These normalised intensities were then log10-transformed
prior to all bioinformatics analyses, and their direct com-
parison enabled the relative quantitation of pY sites be-
tween the p53, PyMT and HER2 GEM models of breast
cancer.
Bioinformatics
Raw MaxQuant output files were subjected to the fol-
lowing filtering criteria prior to their inclusion in further
bioinformatics analysis: (1) contaminants and reversed
matches were removed, ensuring that all identifications
were reported with an FDR of <1%; and (2) pY sites were
filtered for a minimum localisation probability confidence
of 0.75.
Imputation
The k-nearest neighbour [34] method was applied to
impute missing values if a pY site was present in more
than 50% of all samples; otherwise, the minimal value
across all samples or the overall mean per sample for
that pY site was used to replace missing values.
Clustering and heat map generation
Heat maps were generated using the R package gplots
with hierarchical clustering applied to generate dendro-
grams for pY sites and samples. Euclidean distance with
complete linkage was used, and the values were stan-
dardised at rows. The Bioconductor package limma was
used to identify differences between the cancer models
based on their pY-site expression levels. Empirical Bayes
moderated P-values for contrasting and comparing ex-
pression between all samples were corrected for multiple
testing by the Strimmer method as implemented in the
R package fdrtool [35]. For all tests, Q-values less than
0.05 were considered significant. pY sites were thoughtof as class-specific (Her2-specific, p53-specific, PyMT-
specific) on the basis of their contrast significance and the ex-
hibition of increased spectral intensity for a particular sample.
Random forest classifier
The random forest classifier [36] was built using a two-
step approach with the R package randomForest 2.15.0.
In the first step, a classifier was built using all 381 con-
sistently identified pY sites (that is, ≥75% of samples) as
variables. In the second step, 17 pY sites with the importance
score > 1.2 for each tumour model, which were calculated
from the first classifier using a permutation-based approach,
were used to build a new classifier. The out-of-bag estimate
of error rates is 4.76% for both classifiers.
Network analysis
The protein–protein interaction data were extracted from
Protein Interaction Network Analysis (PINA) [37,38]; sub-
strate–kinase relationship information was obtained from
PhosphoSitePlus [39]; and mouse-human orthologues ex-
tracted from MSOAR [40]. The networks were generated
using a Cytoscape PINA4MS plugin (HC Lee, M Pinese, L
Bourbon, I Rooman, RJ Daly, AV Biankin, J Wu, manu-
script under preparation. URL: http://apps.cytoscape.org/
apps/pina4ms).
Pathway analysis
The KOBAS web server [41,42] was applied for pathway
enrichment analysis. The hypergeometric test was used
to calculate the statistical significance of each pathway,
followed by multiple test correction using the Benjamini–
Hochberg method [43].
Antibodies and immunoblotting
Antibodies against the following proteins were used,
with immunoblotting carried out as previously described
[44]: IRS1 (Upstate Biotechnology, Lake Placid, NY, USA);
IRS1 pY612 (Invitrogen), Stat3, Crkl, Jak-1, P85α, CDK16,
Cav1, ErbB3, phospho-ErbB3 (Tyr1328; Tyr1325 in mouse),
ErbB2, Met, Met pY1234/1235 and pY (P-Tyr-100) (Cell
Signaling Technology); phospho-p85 (Tyr467) (GeneTex,
Irvine, CA, USA); platelet-derived growth factor receptor
α (PDGFRα) and β-actin (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); ERBB receptor feedback inhibitor
1 (Errfi1) (Sigma-Aldrich, St Louis, MO, USA).
DNA extraction
Mouse tumour samples and liver tissue samples were
harvested, snap-frozen and processed using the QIAamp
DNA Mini Kit (QIAGEN, Valencia, CA, USA) according
to the manufacturer’s instructions. Briefly, up to 25 mg
of frozen tissue was ground and digested with proteinase
K overnight at 56°C. DNA was purified on a QIAamp
spin column, eluted in 200 μl of water and assessed for
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Scientific, Waltham, MA, USA). Samples were cleaned
up by sodium acetate/ethanol precipitation to ensure
260/280 and 260/230 absorbance ratios >1.8. DNA integ-
rity was checked using gel electrophoresis.
Array comparative genomic hybridisation
Array comparative genomic hybridisation (aCGH) was
performed by The Ramaciotti Centre for Gene Function
Analysis (Randwick, NSW, Australia) on differentially
labelled tumour DNA (Cy5) and sex-matched reference
liver DNA (Cy3) using the Agilent SurePrint G3 mouse
CGH 4 × 180 K microarray platform (Agilent Technologies,
Santa Clara, CA, USA). The aCGH data were analysed
using circular binary segmentation [45] to translate
intensity measurements into regions of equal copy num-
bers. The raw array data were median-normalised; du-
plicate probes were averaged; and the resulting data
were smoothed to remove outliers prior to segmentation.
The gain and loss status for each region was assigned by
determining plateaus in an ordered plot of all segments
by their mean log2 ratios. By this method, we denoted
deletions to be segments with a mean value less than −0.5,
amplifications to have mean value between 0.5 and 1.5
and highly amplified regions to have a mean value greater
than 1.5. Using this information, we merged segmental
values across the genome to create a common set of copy
number levels for each individual tumour. Analysis was
carried out using the Bioconductor DNAcopy package
[46] in R Project R2.15.2 software [47].
Met inhibitor experiments
Tumours were harvested and cellular preparations made
using mechanical disruption and collagenase digestion
as described previously [30]. Cells were cultured in vitro
for two passages in mouse mammary epithelial cell media
consisting of Dulbecco’s modified Eagle’s medium/Ham’s
F12 nutrient mixture supplemented with foetal calf serum,
mouse epidermal growth factor, hydrocortisone, HEPES,
insulin, gentamicin and penicillin/streptomycin [30], then
trypsinised and seeded into 96-well plates at a density of
6,000 cells/well. The following day, cells were treated
with the Met inhibitor PHA-665752 (Selleck Chemicals,
Houston, TX, USA) at concentrations of 0.25 μM, 0.5 μM
and 1 μM or vehicle treated with 0.1% dimethyl sulphoxide
(DMSO; Sigma-Aldrich). Cell proliferation was assessed
and recorded using the IncuCyte ZOOM system (Essen
BioScience, Ann Arbor, MI, USA). Briefly, cells were cul-
tured for 5 days while images of cells inside each well
(three images per well across four replicate wells) were
captured every 2 hours. Proliferation was measured at each
time point as a percentage of confluence, as determined
using the IncuCyte software on the basis of automated ana-
lysis of captured images. Data are representative of tworeplicate experiments. For immunoblotting studies, cells at
70% to 90% confluence were treated with either vehicle
control (DMSO) or Met TKI (1 μM final concentration)
for 1 hour and then lysed in 1% (vol/vol) Triton X-100 lysis
buffer as previously described [48].
Met knockdown and cell proliferation assay
Met knockdown was performed using either individual
(ON-TARGETplus Met siRNA 1 and 2) or SMARTpool
siRNA targeting mouse Met (Dharmacon, Lafayette, CO,
USA). The ON-TARGETplus nontargeting pool was used
as a negative control. Briefly, cells were seeded into 96-well
plates at a density of 4,500 cells/well 16 hours prior to
transfection with 20 nM of siRNA using Lipofectamine
2000 reagent (Invitrogen). Cell proliferation was assessed
by MTS assay ([3-(4,5-dimethyl-2-yl)-5-(3-carboxymetho-
xyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;
Promega, Madison, WI, USA), according to the manufac-
turer’s protocol, 72 hours posttransfection.
Results
Tyrosine phosphorylation profiling of mouse mammary
tumour models
Because the mammary gland develops postnatally, murine
mammary epithelium can be transferred into the surgi-
cally cleared fat pads of juvenile isogenic naïve recipients.
The use of GEM as donors, or viral transduction of cells
after extraction, allows the rapid generation of chimeric
models in which implanted transgenic or gene-knockout
mammary epithelium develops in an otherwise wild-type
host [21,26]. Exploiting this strategy, we performed phos-
phoproteomic profiling using a combined immunoaffin-
ity/LC-MS/MS approach across multiple MSCV-Neu
(HER2), Tp53-null (p53) and PyMT tumours, as illustra-
ted in Figure 1A. The lineage of each tumour from its ori-
ginal clone is outlined in Additional file 1: Figure S1A. In
total, 856 unique pY sites were identified and quantitated
from the tumour sample population with a FDR <1%. Fol-
lowing high-confidence localisation site filtering at ≥0.75,
763 unique pY sites from 506 unique phosphoproteins
remained, with approximately 63% being common across
all tumour types (Figure 1B and Additional file 2: Table S1).
These pY sites mapped to 506 unique proteins. These
proteins, which were grouped based on Gene Ontology
functional categories, are illustrated in Additional file 3:
Figure S2A. Additional file 3: Figure S2B shows an expan-
ded section of the kinases identified in the three tumour
types. The largest proportion of kinases comprised serine/
threonine kinases, followed by non-RTKs and RTKs. The
least represented group comprised the dual-specificity
kinases. The total pY site intensities were determined
for the non-RTKs, which are shown in Additional file 3:
Figure S2C. The most intense signal from the pY sites of
non-RTKs was derived from SFKs (Yes, Fyn, Lyn and
AB C
Figure 1 An overview of the workflow and mass spectrometric phosphotyrosine profiling of mouse tumours. (A) Schematic of the
workflow in this study. Ab, Antibody; IP, Immunoprecipitation; nanoLC-MS/MS, Nano-liquid chromatography tandem mass spectrometry; PyMT,
Polyoma virus middle T antigen. (B) Distribution and overlap of the 763 phosphotyrosine (pY) sites identified in the three mouse tumour models.
(C) Distribution and overlap of the 381 highly reproducible pY sites identified in the three mouse tumour models.
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approach was applied to RTKs, the most intense signal
was derived from Met, followed by EphA2 (Additional
file 3: Figure S2D).
To compare tyrosine phosphorylation patterns be-
tween the different tumour types and identify potential
similarities, we undertook unsupervised hierarchical clus-
tering. This revealed that two p53 tumour samples formed
a distinct subgroup characterised by markedly elevated ty-
rosine phosphorylation of many pY sites (Additional file 4:
Figure S3). The remaining tumour samples were distrib-
uted over a second major subgroup and exhibited a com-
plex pattern of relationships. Of note, five PyMT tumours
were closely related, and the majority of the p53 and HER2
tumours clustered together (Additional file 4: Figure S3).
Also, although some tumours of shared origin, such as p53
tumours 1203 and 1204, clustered together, others, such as
HER2 tumours HER 1197 and 3051, were well separated(Additional file 1: Figure S1B), indicating that divergence
can occur following serial transplantation.
To generate a list of pY sites characteristic of each
tumour type, we first identified pY sites detected in at
least 75% of the corresponding samples. Therefore, we
selected pY sites that were identified in at least (1) six of
eight p53 tumour samples, (2) six of eight PyMT tumour
samples or (3) four of five Her2 tumour samples. Follow-
ing this selection-filtering process, 381 pY sites remained
(Figure 1C and Additional file 5: Table S2). These sites
mapped to 256 proteins, with 177 of them being found in
all three tumour types. Upon unsupervised hierarchical
clustering of this refined data set, all of the PyMT tumours
were clustered together (Additional file 6: Figure S4). How-
ever, p53 tumours 1203 and 1204 still formed a distinct
subgroup, and the HER2 tumours were divided into two
groups, one related to PyMT tumours and the other to
p53 tumours (Additional file 6: Figure S4).
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ticular tumour type versus the other two, an analysis of
variance (ANOVA)–based approach was implemented.
Thirty-two pY sites were upregulated in HER2 tumours,
eighty-six in p53 tumours and eighty in PyMT tumours
(Additional file 5: Table S2). Of note, certain proteins
exhibited site-selective variation in phosphorylation be-
tween different tumour types, examples being Tln1 and
Cbl. Elevated levels of Erbb3 pY1325 and p85 pY467 in
PyMT tumours were confirmed by Western blot analysis
with appropriate phosphospecific antibodies (Additional
file 7: Figure S5). Immunoblotting for selected targets
revealed that, for certain pY sites characteristic of a given
subtype, elevated phosphorylation was accompanied by
increased expression of the given protein. This was ex-
emplified by Irs1 and Pik3r1 (p85) in PyMT tumours
(Figure 2A and B). However, for others, the increased
phosphorylation must reflect a change in relative phos-
phorylation, as for Erbb3 in PyMT tumours, Cdk16 in
p53 tumours and Erffi1 in HER2 tumours (Figure 2C
to E). References for the sites characterised in this figure
are provided in PhosphoSite [49].
We also developed and applied a random forest classi-
fier to identify 17 highly variable pY sites that can be
used to distinguish between the tumour types (Figure 3).
Amongst these, elevated phosphorylation of Pik3r1, Pik3r3,
a G protein–coupled receptor (Gprc5c) and an uncha-
racterised protein (2310030G06Rik) was specific to PyMT
tumours, and p53 tumours were characterised by increased
phosphorylation of Vim, Ptrf, Vcl, Fgr, Met and a protein
related to heat shock protein 70 kDa. Elevated tyrosine
phosphorylation of Errfi1 characterised HER2 tumours.
Pathway and protein–protein interaction analysis
Lists of pY sites enriched in each tumour type were then
subjected to bioinformatics analysis to identify associated
pathways or biological processes (Table 1). Strikingly,
marked differences were observed between p53, HER2
and PyMT tumours. The former exhibited an enrichment
of processes linked to cytoskeletal reorganisation, with the
top five significant terms being leucocyte transendothelial
migration, bacterial invasion of epithelial cells, regulation
of actin cytoskeleton, focal adhesion and muscle contraction.
The only term significantly enriched for HER2 tumours was
the ErbB signalling pathway, whereas the PyMT tumours
were characterised by processes involving PI3K signalling,
including type 2 diabetes mellitus, the FcεRI signalling path-
way, acute myeloid leukaemia, Fcγ receptor–mediated
phagocytosis and the neurotrophin signalling pathway.
Significantly upregulated pY sites (determined by
ANOVA) characteristic of each tumour type were ana-
lysed using PINA [37,38] (Figures 4, 5 and 6). Where
available, consensus lists were searched against mouse
data sets containing previously reported interaction data;however, in cases where interactions were not reported in
mouse data sets, human orthologues were used to model
potential interactions. In addition, kinase substrate rela-
tionships were extracted from PhosphoSitePlus [39]. A
key characteristic of p53 tumours was the presence of a
major protein–protein interaction hub composed of sev-
eral proteins involved in cytoskeletal organisation (Actn1,
Actn4, Sept7, Sept 9 and Plec), as well as a further hub
centred on Itgb1 (Figure 4). The latter involved numerous
proteins localised to focal adhesions, including Bcar1,
Tln1, Pxn and Vcl. These findings are in agreement with
the corresponding pathway analysis (Table 1). Further-
more, there are notable similarities between this network
and that present in human basal and claudin-low breast
cancer cell lines [16], including increased tyrosine phos-
phorylation of Met, Cav1, Bcar1 and Tln1. This is consist-
ent with previous reports that subsets of p53 tumours
exhibit gene expression signatures characteristic of these
breast cancer subgroups [21,22]. In contrast, HER2 tu-
mours exhibited a protein–protein interaction network
that reflected the relationship between HER2 and its asso-
ciating substrates (for example, Cbl, Ptpn11, Plcγ1), but it
is noteworthy that Egfr and Pdgfrα, as well as the feed-
back inhibitor Errfi1, are also components of this network
(Figure 5). Consistent with the pathway analysis, PyMT
tumours exhibit a major interaction hub that centres on
the PI3K regulatory subunit Pik3r1 (Figure 6). Interest-
ingly, in addition to PyMT itself, this hub involves two
RTKs (Kit and Erbb3) and two docking proteins (Irs1 and
Gab1) that are well-characterised binding partners for
Pik3r1. Although Src is required for efficient induction
of mammary tumours by PyMT [50], increased phos-
phorylation of Y416 on the Src activation loop (a peptide
sequence conserved amongst SFKs) or Src-selective pep-
tides was not detected in PyMT tumours. However, three
additional SFKs—Yes, Lyn and Hck—exhibited increased
phosphorylation on unique peptide sequences and resided
within the network (Figure 6). The former is known to
interact with PyMT [19] but is not essential for PyMT-
induced mammary tumourigenesis [50].
Subclassification of p53 tumours
In a previous study on the Tp53-null mouse mammary
tumour model, researchers demonstrated that the gener-
ated tumours exhibit considerable heterogeneity and can
be classified by transcript profiling into a variety of mo-
lecular subtypes, including one luminal, one claudin-low
and two basal-like subtypes [22]. To interrogate this poten-
tial heterogeneity at the level of tyrosine phosphorylation
patterns, we undertook unsupervised hierarchical cluster-
ing of the p53 tumours based on all phosphorylation sites
detected in these tumours (Additional file 8: Figure S6).
Tumours 1203 and 1204 clustered together and were cha-
racterised by markedly elevated (greater than tenfold)
CE
D
A B
Figure 2 Comparison of expression and tyrosine phosphorylation of specific proteins. Immunoblot quantitation of total protein expression
compared with relative tyrosine phosphorylation of the corresponding protein, obtained by mass spectrometry (MS). Green represents low
phosphotyrosine (pY) peptide abundance as measured by MS, and red indicates high pY peptide abundance. The heat maps indicate the
intensity of phosphorylation on the following specific sites: (A) IRS-1 (pY608), (B) p85 (pY467), (C) ErbB3 (pY1325), (D) CDK16 (pY176) and (E) Errfi1
(pY393). Blue bars represent actin-normalised immunoblot intensities for the proteins indicated. PyMT, Polyoma virus middle T antigen.
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compared to the remainder of p53 tumours (Additional
file 9: Table S3). Tumour 14845 also exhibited relatively
high tyrosine phosphorylation of many proteins, but
not to the same extent as tumours 1203 and 1204, andtumours 3049, 1201 and 1202 displayed elevated phos-
phorylation of more distinct protein subsets. Tumours
1205 and 1206 were characterised by relatively low levels
of tyrosine phosphorylation. Hypothesizing that the ex-
tremely high levels of tyrosine phosphorylation in tumours
Figure 3 Unsupervised hierarchical clustering using the 17–pY site tumour type classifier identified using random forest classification.
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Table 1 Top ten pathways/biological processes for each tumour typea
Term Corrected
P-value
Accession Gene name
p53
Leucocyte transendothelial
migration
7.87E-05 P70460|Q61140|P26040|P26041|Q64727|Q8VI36|P57780|
Q7TPR4|P09055
Vasp|Bcar1|Ezr|Msn|Vcl|Pxn|Actn4|Actn1|Itgb1
Bacterial invasion of
epithelial cells
<0.01 P22682|Q61140|Q64727|Q8VI36|Q9JM76|P49817|P09055 Cbl|Bcar1|Vcl|Pxn|Arpc3|Cav1|Itgb1
Regulation of actin
cytoskeleton
<0.01 Q61140|P26040|P26041|Q7TPR4|Q64727|Q8VI36|P26043|
P57780|Q9JM76|P09055
Bcar1|Ezr|Msn|Actn1|Vcl|Pxn|Rdx|Actn4|Arpc3|Itgb1
Focal adhesion <0.01 P70460|P26039|Q61140|Q64727|Q8VI36|P57780|Q7TPR4|
P49817|P09055
Vasp|Tln1|Bcar1|Vcl|Pxn|Actn4|Actn1|Cav1|Itgb1
Muscle contraction <0.01 P62204|Q64727|P20152|Q8VI36|P26039 Calm1|Vcl|Vim|Pxn|Tln1
Haemostasis <0.01 P12023|P20491|P26039|Q61140|Q91YI4|P14234|P48025|
P57780|Q7TPR4|P49817|P09055
App|Fcer1g|Tln1|Bcar1|Arrb2|Fgr|Sykb|Actn4|Actn1|
Cav1|Itgb1
Fcγ receptor–mediated
phagocytosis
0.02 Q9JM76|P70460|P08103|Q9ES52|P48025 Arpc3|Vasp|Hck|Inpp5d|Sykb
Adherens junction 0.05 Q9D358|P57780|Q7TPR4|Q64727 Acp1|Actn4|Actn1|Vcl
Cell–cell communication 0.05 Q80W68|Q9QXS1|Q7TPR4|P09055|Q3UND0 Kirrel|Plec|Actn1|Itgb1|Skap2
Endocytosis 0.12 P22682|Q91YI4|P01899|Q99LI8|Q62351|P49817 Cbl|Arrb2|H2-D1|Hgs|Tfrc|Cav1
Her2
ErbB signalling pathway 3.79E-02 P70424|Q01279|P47941|P22682|Q62077 Erbb2|Egfr|Crkl|Cbl|Plcγ1
Disease 0.09 Q99LI8|P35235|Q01279|P22682|Q62077 Hgs|Ptpn11|Egfr|Cbl|Plcγ1
Non–small-cell lung cancer 0.16 P70424|Q01279|Q62077 Erbb2|Egfr|Plcγ1
Pathways in cancer 0.16 P22682|Q62077|P47941|Q01279|P26618|P70424|P97807 Cbl|Plcγ1|Crkl|Egfr|Pdgfrα|Erbb2|Fh1
Glioma 0.16 Q62077|Q01279|P26618 Plcγ1|Egfr|Pdgfrα
Focal adhesion 0.16 P70424|Q01279|P47941|P26039|P26618 Erbb2|Egfr|Crkl|Tln1|Pdgfrα
Renal cell carcinoma 0.16 P35235|P47941|P97807 Ptpn11|Crkl|Fh1
Neurotrophin signalling
pathway
0.16 O08911|P35235|P47941|Q62077 Mapk12|Ptpn11|Crkl|Plcγ1
Chronic myeloid leukaemia 0.16 P35235|P47941|P22682 Ptpn11|Crkl|Cbl
Developmental biology 0.16 P35235|P70424|Q01279|P26039|Q62077 Ptpn11|Erbb2|Egfr|Tln1|Plcγ1
PyMT
Type 2 diabetes mellitus 3.08E-02 P35569|Q64143|Q63844|P26450|P28867 Irs1|Pik3r3|Mapk3|Pik3r1|Prkcd
FcεRI signalling pathway 0.03 P28867|Q63844|P25911|Q64143|Q9Z1B7|P26450 Prkcd|Mapk3|Lyn|Pik3r3|Mapk13|Pik3r1
Acute myeloid leukaemia 0.03 Q64143|Q63844|P05532|P26450|P42227 Pik3r3|Mapk3|Kit|Pik3r1|Stat3
Fcγ receptor–mediated
phagocytosis
0.04 P28867|Q63844|P08103|Q64143|P25911|P26450 Prkcd|Mapk3|Hck|Pik3r3|Lyn|Pik3r1
Neurotrophin signalling
pathway
0.04 P35569|P28867|Q63844|Q64143|Q9Z1B7|Q9QYY0|
P26450
Irs1|Prkcd|Mapk3|Pik3r3|Mapk13|Gab1|Pik3r1
Aldosterone-regulated
sodium reabsorption
0.04 P35569|Q64143|Q63844|P26450 Irs1|Pik3r3|Mapk3|Pik3r1
ErbB signalling pathway 0.09 Q9QYY0|Q63844|P26450|Q61526|Q64143 Gab1|Mapk3|Pik3r1|Erbb3|Pik3r3
Cell–cell communication 0.10 Q80W68|P30999|P26450|Q9Z1B7 Kirrel|Ctnnd1|Pik3r1|Mapk13
Hepatitis C 0.10 Q63844|Q9Z0G9|Q64143|Q9Z1B7|P42227|P26450 Mapk3|Cldn3|Pik3r3|Mapk13|Stat3|Pik3r1
Chemokine signalling
pathway
0.12 P28867|Q63844|P08103|Q64143|P42227|P25911|P26450 Prkcd|Mapk3|Hck|Pik3r3|Stat3|Lyn|Pik3r1
aPyMT: Polyoma virus middle T antigen. Significantly enriched terms are shown in bold.
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Figure 4 Protein Interaction Network Analysis of proteins exhibiting significantly enhanced tyrosine phosphorylation in the p53
tumour model. The direct protein–protein interactions are indicated by lines, with blue and red lines representing data from mouse and human
orthologue databases, respectively. Interactions that have been described previously in both human and mouse are indicated by yellow lines.
Kinase substrate relationships are indicated by arrows.
Figure 5 Protein Interaction Network Analysis of proteins exhibiting significantly enhanced tyrosine phosphorylation in the Her2
tumour model. The protein–protein interactions are indicated as described for Figure 4.
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Figure 6 Protein Interaction Network Analysis for proteins exhibiting significantly enhanced tyrosine phosphorylation in the polyoma
virus middle T antigen tumour model. The protein–protein interactions are indicated as described for Figure 4.
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http://breast-cancer-research.com/content/16/5/4371203 and 1204 might reflect upregulation of a particular
tyrosine kinase in these two tumours, we noted that
several of the upregulated pY sites were from Met, specif-
ically Y1228, Y1232, Y1233, Y1347 and Y1354 (Figure 7).
In addition, Y6 and Y14 on Cav1 also exhibited increased
phosphorylation, which was of interest, given the close
proximity of the Met and Cav1 genes on mouse chro-
mosome 6 and coamplification of these two genes in par-
ticular tumour types [51-53]. Immunoblotting for Met
and Cav1 revealed markedly increased total protein ex-
pression in the p53 samples from tumours 1203 and 1204
(Figure 8A and B). In addition, aCGH was performed on
the p53 tumours. This revealed that, though p53 tumours
1201, 1205, 1206 and 14845 exhibited small (two- to three-
fold) increases in copy number for regions of chromosome
6 harbouring Met and Cav1, tumours 1203 and 1204
displayed 20- and 25-fold amplifications, respectively,
of a chromosomal segment spanning these two genes
(Figure 8C and D and Additional file 10: Table S4).
Having demonstrated that tumours 1203 and 1204 are
characterised by Met gene amplification, we compared
the tyrosine phosphorylation profile of these two tu-
mours versus the other p53-null tumours in more detail.
Consistent with enhanced Met signalling, tyrosine phos-
phorylation of Hgs, which regulates Met endocytic traf-
ficking [54], was markedly elevated (Additional file 9:Table S3). These tumours were also characterised by in-
creased tyrosine phosphorylation of Ptrf/cavin, which is
localised with Cav1 to caveolae, and of the RTK Axl and
the docking protein Dock1 (Additional file 9: Table S3).
Interestingly, pathway analysis revealed that tumours
1203/1204 demonstrated significant enrichment for the
term glycolysis/gluconeogenesis, reflecting increased tyro-
sine phosphorylation of several metabolic enzymes, includ-
ing Pgam1, Pkm2 and Pgk1 (Additional file 11: Table S5).
To gain insight into the functional role of Met in the
p53 tumours, we established cell lines from tumours
1201 and 1206 (low-level Met gene amplification) and
tumour 1204 (high-level Met amplification). Pretreat-
ment of these cell lines with the Met TKI PHA-665752
decreased Met phosphorylation on Y1234/Y1235 and
markedly reduced the elevated cellular tyrosine phosphoryl-
ation levels in tumour 1204 cells (Figure 9A). Importantly,
though administration of the Met TKI at a concentration
(1 μM) that ablated Met tyrosine phosphorylation had no
effect on proliferation in tumour 1201 cells (Figure 9B),
this treatment markedly attenuated proliferation of tumour
1204 cells (Figure 9C). As an alternative and comple-
mentary approach, we knocked down Met expression
using selective siRNAs (Additional file 12: Figure S7). Met
knockdown had only a modest effect in the 1201 and 1206
tumour cell lines, but markedly attenuated proliferation in
Figure 7 Unsupervised hierarchical clustering using the 150 most variable phosphotyrosine sites identified in the p53 tumours.
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(P < 0.005 for comparisons of Met knockdowns in the 1201
or 1206 tumour cell line versus the 1204 tumour cell line).
These data indicate that the extremely high levels of tyro-
sine phosphorylation detected in tumour 1204 (Figure 7)
are dependent on Met activity, and that cells from these
tumours are addicted to Met activation for their prolifera-
tion in vitro.
Interrogation of the tyrosine phosphorylation patterns
characteristic of the other p53-null subgroups revealed
that phosphorylation of the atypical kinase Peak1/SgK269
[55] was elevated in tumour 14845 and to a lesser extent
the subgroup containing 3049, 1202 and 1201, whereas
phosphorylation of Prex2 characterised tumours 14845
and 3049, where it was accompanied by enhanced phos-
phorylation of Pik3r2 (Figure 7). Taken in association withour demonstration of Met amplification in tumours 1203
and 1204, these findings highlight the power of tyrosine
phosphorylation profiling to identify candidate oncogenic
drivers [56].
Discussion
Specific genetically modified mouse models of breast can-
cer have made major contributions to our understanding
of the role of particular oncogenes in the development
of this malignancy [18]. In addition, characterisation of
tumours arising in these models by approaches such as
transcript profiling and aCGH have identified molecular
aberrations conserved between mouse and human mam-
mary tumours that are likely to represent key ‘driver’
events [21,22,57]. However, to date, no comprehensive
characterisation of the tyrosine kinase signalling networks
AC
D
B
Figure 8 Protein expression, tyrosine phosphorylation and gene copy number for Met and Cav1. (A) and (B) Immunoblot quantitation of
total protein expression compared with relative tyrosine phosphorylation of the corresponding protein obtained by mass spectrometry. Data
are presented as in Figure 2. Colour key and histogram apply to (A) and (B). The heat maps indicate the intensity of phosphorylation on the
following specific sites: MET (pY1354) and Cav1 (pY14). (C) Array comparative genomic hybridisation profile of mouse chromosome 6 in the
different p53 tumours, showing the 1,556-kb stretch where the genes for Cav1 and Met are located. (D) Lower-resolution view of the amplified
region. The intensity of blue or red indicates gene copy number. Heat map in (C) also applies to (D).
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study, we used MS-based global tyrosine phosphorylation
profiling to characterise three commonly used mouse
models of breast cancer, which revealed distinct differ-
ences between these models and features conserved with
subtypes of the human disease.For an erbB2 model, we used a truncated form of Neu
[26,27] that models a form of erbB2 lacking the extracellular
domain present in approximately 30% of HER2-positive
breast cancer patients, for whom it is associated with a
worse prognosis [58]. This form exhibits potent oncogenic
activity [59]. These tumours were characterised by
A B
C
Figure 9 Effects of MET inhibition on p53-null tumour-derived cell lines. (A) Effect of the Met tyrosine kinase inhibitor (TKI) PHA-665752 on
cellular tyrosine phosphorylation in different p53-null tumour-derived cell lines. Cell lysates were subjected to Western blot analysis as indicated.
(B) and (C) Effect of Met inhibition on proliferation of cells with low (tumour cell line 1201, B) and high (tumour cell line 1204, C) levels of Met
gene amplification. IB, Immunoblot.
Ali et al. Breast Cancer Research 2014, 16:437 Page 15 of 19
http://breast-cancer-research.com/content/16/5/437increased phosphorylation of several signalling molecules
known to associate with erbB2, including Ptpn11, Plcγ1,
Cbl and CrkL, as well as its heterodimerisation partner
Egfr. Given the known heterodimerisation of full-length
erbB2 and erbB3, our finding that phosphorylation of
erbB3 Y1325 was not elevated in the majority of HER2
tumours (expressing truncated neu), despite increased
erbB3 expression (Figure 2), is surprising and warrants
further investigation in cell culture models and clinical
specimens. Additional novel findings include enhanced
tyrosine phosphorylation of Errfi1 and Pdgfrα. The former
represents a negative feedback regulator of erbB signalling
that inhibits EGFR and erbB2 kinase activity by binding
directly to the receptor kinase domain and blocking the
formation of the activating dimer interface [60]. However,
although increased expression of Errfi1 is associated with
high erbB receptor signalling [61], expression of Errfi1
was similar between HER2 and p53 tumours, indicating
that it is the relative tyrosine phosphorylation of Errfi1 on
Y393/Y394 that is altered. Importantly, phosphorylation
of Errfi1 on Y394 reduces its ability to inhibit Egfr [62],indicating that this modification may act to attenuate
negative regulation of HER2 signalling by Errfi1 in these
tumours. Consequently, it will be of great interest to
determine how expression of Errfi1, and also its tyrosine
phosphorylation, relate to HER2 expression and outcome
in breast cancer patients.
The finding of increased Pdgfrα phosphorylation is of
interest because autocrine Pdgf action is associated with
TGF-β-induced epithelial–mesenchymal transition (EMT)
in MMTV-Neu mammary tumours and because increased
Pdgfrα and Pdgfrβ expression occur in late-stage, invasive
human breast cancers [63]. Researchers in a previous
study demonstrated that a truncated form of HER2, simi-
lar to that used in this study, specifically induced the
expression of a set of genes involved in cancer cell spread
and associated with poor patient prognosis [59]. Thus, the
induction of Pdgfrα signalling in our model may reflect
the oncogenic potency of the truncated form of Neu
utilised and the occurrence of EMT.
A previous study on the PyMT model revealed a depen-
dence on PI3K activation for efficient tumourigenesis
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of the p85 binding sites on PyMT [20], our pathway and
protein–protein interaction analyses on the tyrosine-phos-
phorylated proteins selectively enriched in these tumours
also support a key role for PI3 kinase signalling in this
tumour type. These results highlight the presence of
other p85 binding proteins in these tumours in addition
to PyMT itself, including erbB3, Gab1 and Irs1. All of
the latter three proteins have been characterised as positive
regulators of PI3K signalling [64]. In addition, enhanced
tyrosine phosphorylation of p85a on several sites was
detected in these tumours. Tyrosine phosphorylation of
p85a on Y688 has been reported to relieve its inhibitory
activity on PI3K [65]; however, we did not detect phos-
phorylation on this site in our present study, and the func-
tional role of the p85a phosphorylation events enhanced
in PyMT tumours requires further characterisation.
An important question is the identity of the tyrosine
kinases driving PyMT tyrosine phosphorylation. It is well
established that PyMT associates with, and is phosphory-
lated by, the SFKs Src and Yes, and also that expression of
Src is essential for efficient PyMT-induced tumourigenesis
[19,50]. However, in a recent article, researchers reported
that PyMT associates with the RTK erbB2 and the catalyt-
ically impaired erbB3 and that both erbB2 activity and
erbB3 expression are essential for PyMT transforming ac-
tivity [66]. These data, together with those published by
the Muller group [50], indicate that erbB2 may act upstream
of Src in this model. However, we could detect only erbB3-
derived, and not erbB2-derived, tyrosine-phosphorylated
peptides in the majority of PyMT tumours. A potential ex-
planation is that one or more RTKs may substitute for
erbB2 in this model. Because Egfr phosphorylation was
detected and phosphorylation of Kit was enhanced in this
tumour type, these RTKs represent potential candidates.
The p53 tumour model exhibits heterogeneity at the
histological and gene expression levels, and, on the basis
of the latter parameter, can be classified into different
molecular subgroups, including basal-like, claudin-low
and luminal subtypes [22]. Although we profiled only
eight p53 tumours, our data are consistent with the ability
of this model to generate tumours with a basal or claudin-
low phenotype. First, there was notable overlap between
the identified signalling networks in these tumours and
basal and claudin-low breast cancer cells [16]. Second,
tyrosine-phosphorylated proteins characteristic of p53
tumours exhibited an enrichment for pathways associated
with cytoskeletal organisation, in concordance with the
observed mutational spectrum reported for triple-negative
breast cancers [67]. Third, two of the p53 tumours exhib-
ited markedly enhanced tyrosine phosphorylation of many
cellular proteins, including Met, and this was associated
with high-level amplification of a segment of chromosome
6 that contains the Met and Cav1 genes. This is consistentwith high expression and amplification of the MET gene
in human basal breast cancers [13,15,68] and amplification
of the Met/Cav1 locus in basal-like mammary tumours in
mice with mammary-specific deletion of Lfng [52]. In
addition, researchers in a recent study demonstrated that
transgenic Met overexpression in the mouse mammary
gland cooperates with conditional p53 loss to drive the
formation of claudin-low mammary tumours, and they
showed that claudin-low tumours developing in mice
without the MMTV-Met transgene and only conditional
mammary gland-specific deletion of p53 exhibited amplifi-
cation of the endogenous Met gene [69]. These data are in
concordance with our data demonstrating Met amplifica-
tion in a subset of p53-null mammary tumours and high-
light the potential utility of transplantable tumours 1203
and 1204 and the MMTV-Metmt;Trp53fl/+;Cre model
generated by the Park group [69] as preclinical models in
which to test Met-directed therapies for triple-negative
breast cancer. Indeed, our data indicate that p53-null cells
with high-level Met amplification are dependent on Met
activation for their continued proliferation.
Our finding that tumours 1203 and 1204 demonstrated
increased tyrosine phosphorylation of several enzymes
involved in glycolysis and gluconeogenesis indicates that
this tumour subset is likely to exhibit altered metabolic
properties. Indeed, tyrosine phosphorylation of both Pkm2
Y105 and Pgam1 Y26 regulates their activity and, by
modulating aerobic glycolysis and anabolic biosynthesis,
promotes tumourigenesis [70,71]. In light of these findings,
it will be important to determine whether MET-amplified
human breast cancers exhibit corresponding metabolic
changes and whether the altered metabolism confers an
‘Achilles heel’ amenable to therapeutic intervention.
The identification of two p53 tumours exhibiting Met
gene amplification highlights how mouse models of
mammary tumourigenesis can be used to identify breast
cancer oncogenic ‘drivers’. Of note, our phosphoproteomic
profiling of p53 tumours identified markedly enhanced
tyrosine phosphorylation of Peak1/SgK269 and Prex2 in
other p53-null tumour subsets. The former protein is an
atypical kinase recently demonstrated to exhibit char-
acteristics of a breast cancer oncogene, and site-selective
Peak1/SgK269 tyrosine phosphorylation promotes bio-
logical activity [55]. Prex2 is a negative regulator of PTEN
(phosphatase and tensin homologue) and is mutated in
melanoma [72], although the role of Prex2 tyrosine phos-
phorylation is yet to be determined. Consequently, these
two proteins represent strong candidates for further
functional characterisation and evaluation as therapeutic
targets and biomarkers.
Conclusions
Our finding that three commonly utilised mouse models
of breast cancer are characterised by distinct tyrosine
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portant insights into mechanisms of mammary tumour
development and progression. The identification of Met
as an oncogenic driver in a subset of p53-null tumours
highlights how comparative phosphoproteomics can
identify conserved oncogenic signalling pathways and
identifies a new preclinical model for a subset of triple-
negative breast cancers.Additional files
Additional file 1: Figure S1. (A) The lineage of the different tumour
samples characterised. (B) Clustering relationships in comparison to
tumour of origin for the xenografts. The coloured lines indicate which
tumour transplants share a common origin. The coloured ovals indicate
instances where only one transplant tumour from a particular clonal line
was characterised.
Additional file 2: Table S1. 763 pY sites identified from the pY
profiling of p53, Her2 and PyMT mammary mouse tumours.
Additional file 3: Figure S2. (A) Gene Ontology annotation of the
phosphoproteins identified from the three mouse tumour models.
(B) Proportion of different kinase types identified (based on number
and subclassification). (C) Contribution of different non-receptor
tyrosine kinases, based on pY peptide spectral intensity. (D) Contribution
of different receptor tyrosine kinases based on pY peptide spectral
intensity.
Additional file 4: Figure S3. Unsupervised hierarchical clustering using
all 763 identified pY sites. (Imputation: k-NN + column mean).
Additional file 5: Table S2. 381 highly reproducible pY sites.
Additional file 6: Figure S4. Unsupervised hierarchical clustering using
the 381 pY sites detected in at least 75% of one tumour type.
(Imputation: k-NN+ row min).
Additional file 7: Figure S5. (A) and (B) Immunoblot quantitation of
phosphorylation on specific phosphosites compared with relative
tyrosine phosphorylation on the same sites determined by MS. Data are
presented as in Figure 2, and colour key and histogram apply to (A) and
(B). The heat maps indicate the intensity of phosphorylation on the
following specific sites: ErbB3 (pY1325) and p85 (pY467). The lane
corresponding to tumour 1186 has been removed due to sample
degradation. Because phosphorylation of Y1325 was not detected in
HER2 tumour 3051 by MS, the positive signal obtained by Western
blotting may reflect cross-reactivity of the commercial antibody with a
different phosphorylation site on erbB3 or another erbB receptor.
Additional file 8: Figure S6. Unsupervised hierarchical clustering
using the 707 pY sites identified in p53 tumours. (Imputation:
k-NN + column mean).
Additional file 9: Table S3. Proteins showing >10-fold increased
phosphorylation in 1203/4 versus the other p53 tumours.
Additional file 10: Table S4. Amplified regions on chromosome 6 for
the eight p53 tumours.
Additional file 11: Table S5. Pathway analysis of proteins showing
>10-fold increased phosphorylation in 1203/4 versus other p53 tumours.
Additional file 12: Figure S7. (A) MET knockdown using siRNA in
cell lines derived from p53-null mouse tumours. Western blots were
incubated with the indicated antibodies. # in 1201 indicates nonspecific
band. (B) Effect of MET knockdown on cell proliferation by MTS assay
measuring relative absorbance. At least three independent sets of replicate
experiments were performed with the same trend observed. Data from one
representative experiment are shown. *P < 0.05 and **P < 0.005 by t-test
(siRNA treated vs control). ‘Control’ refers to ON-TARGETplus nontargeting
siRNA, and ‘Pool’ refers to SMARTpool consisting of four individual siRNAs
targeting mouse MET.Abbreviations
aCGH: Array comparative genomic hybridisation; ANOVA: Analysis of
variance; EMT: Epithelial–mesenchymal transition; FDR: False discovery rate;
GEM: Genetically engineered mouse; Gprc5c: G protein–coupled receptor
family C, group 5, member C; IP: Immunoprecipitation; k-NN: k-nearest
neighbour; MMTV: Mouse mammary tumour virus; MS/MS: Tandem mass
spectrometry; nano-LC-MS/MS: Nano-liquid chromatography tandem mass
spectrometry; PI3K: Phosphatidylinositol 3-kinase; PINA: Protein interaction
network analysis; pY: Phosphotyrosine; PyMT: Polyoma virus middle T
antigen; RTK: Receptor tyrosine kinase; SFK: Src family kinase.
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